PLUS1
0.2173
0.0009 (0.42%)
0.0009 (0.42%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data! |
|
Big Cap Pro
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Ocugen Inc | OCGN | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Low Price | High Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| -0.0036 | -1.64% | 0.2164 | 0.2134 | 0.2299 | 0.2214 | 0.22 | 00:00:05 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 0.21 | 0.22 | 0.01 | 4.55% | - | - |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 5,981 | 5,765,681 | $ 0.2179413 | $ 1,256,580 | 14,828,376 | 0.17 - 3.35 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 19:59:40 | formt | 5,625 | $ 0.2173 | USD |
Ocugen Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 23.85M | 110.22M | 105.05M | $ - | $ - | -8.42 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | 75.00k | 2.50% |
Ocugen News
| Date | Time | Source | News Article |
|---|---|---|---|
| 6/16/2020 | 08:46 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 6/12/2020 | 16:36 | Edgar (US Regulatory) | Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) |
| 6/12/2020 | 16:31 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 6/03/2020 | 16:33 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 6/03/2020 | 08:30 | GlobeNewswire Inc. | Ocugen Appoints Dr. Mohamed Genead as Chair of Retina.. |
| 6/01/2020 | 09:23 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 6/01/2020 | 09:20 | GlobeNewswire Inc. | Ocugen to Discontinue Phase 3 oGVHD Trial |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical OCGN Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.22 | 0.245 | 0.20 | 0.2133435 | 7,006,754 | -0.0036 | -1.64% |
| 1 Month | 0.27 | 0.32 | 0.20 | 0.2401172 | 11,382,690 | -0.0536 | -19.85% |
| 3 Months | 0.44 | 0.4998 | 0.17 | 0.2760039 | 10,748,255 | -0.2236 | -50.82% |
| 6 Months | 0.675 | 0.8388 | 0.17 | 0.3384533 | 6,691,815 | -0.4586 | -67.94% |
| 1 Year | 3.24 | 3.35 | 0.17 | 0.4462659 | 6,524,002 | -3.02 | -93.32% |
| 3 Years | 3.24 | 3.35 | 0.17 | 0.4462659 | 6,524,002 | -3.02 | -93.32% |
| 5 Years | 3.24 | 3.35 | 0.17 | 0.4462659 | 6,524,002 | -3.02 | -93.32% |
Ocugen Description
| Ocugen Inc is a clinical-stage biopharmaceutical company. It is focused on discovering, developing and commercializing a pipeline of innovative therapies that address rare and underserved eye diseases. Ocugen offers a diversified ophthalmology portfolio that includes novel gene therapies, biologics, and small molecules and targets a broad range of high-need retinal and ocular surface diseases. Its product candidate includes OCU200 and OCU300 to treat diabetic macular edema (DME), diabetic retinopathy (DR) and wet age-related macular degeneration (AMD). |
